Skip to main content

Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.

Completed · Phase 3 · NCT01996865

Conditions: Lymphoma, Non-Hodgkin

At a glance

Research payments reported, 2025
$641,646
U.S. investigators named
53
Sites paid
42
Planned or actual enrollment
503

About the trial

Sponsor
Celgene
Tested
Lenalidomide (drug), Rituximab (drug)
Dates
Started 2014-04-01; completion 2024-09-17
Results posted
Yes

Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) are distinct histologic types of B-cell NHL. Lenalidomide is an immunomodulatory agent with direct and immune-mediated mechanisms of action, as well as clinical activity in NHL. Recent studies in frontline and relapsed/refractory NHL show high activity for lenalidomide plus rituximab (R2), supporting further study of this combination.

From ClinicalTrials.gov, last updated 2025-07-10. Full record, eligibility and contacts (opens in a new tab)

Industry funding

E.r. Squibb & Sons, L.l.c. reported $641,646 in research payments for this study in 2025 (56 payments).

Products named: Camzyos, Revlimid

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.